Effect of combination therapy with ribavirin and high‐dose interferon‐α2b for 24 weeks in chronic hepatitis C

Abstract

A 24-week course of combination therapy with ribavirin and 6 MU IFN-alpha2b had an acceptable efficacy with fewer adverse events than that with ribavirin and 10 MU IFN-alpha2b in CHC.

The effects of HCV infection and management on health-related quality of life

“…59 SVR rates were higher for the general study population but no different in a subgroup of patients infected with HCV genotype 1b. The proportion of patients who discontinued treatment or reduced drug dosages because of adverse events was significantly higher in the 10 MU group (27% versus 7.7%; P ϭ 0.02).…”

“…The proportion of patients who discontinued treatment or reduced drug dosages because of adverse events was significantly higher in the 10 MU group (27% versus 7.7%; P ϭ 0.02). 59 Studies such as these highlight the impact of study dose and duration on adherence. While no specific HRQL data were collected, it is interesting to speculate whether compromises in HRQL were responsible for greater rates of treatment discontinuation.…”